Citius Pharmaceuticals, Inc. - Common Stock (CTXR)
1.6700
-0.1400 (-7.73%)
NASDAQ · Last Trade: Oct 21st, 3:28 PM EDT
Detailed Quote
Previous Close | 1.810 |
---|---|
Open | 1.660 |
Bid | 1.660 |
Ask | 1.670 |
Day's Range | 1.600 - 1.860 |
52 Week Range | 0.6500 - 12.84 |
Volume | 1,327,166 |
Market Cap | 243.79M |
PE Ratio (TTM) | -0.3360 |
EPS (TTM) | -5.0 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,362,712 |
Chart
About Citius Pharmaceuticals, Inc. - Common Stock (CTXR)
Citius Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapeutic products for critical care and cancer treatment. The company primarily specializes in the formulation and commercialization of medical products that aim to address unmet medical needs in the areas of oncology and critical care medicine. Citius is actively engaged in advancing its product pipeline through clinical trials, emphasizing the development of safe and effective therapies to improve patient outcomes. The company's commitment to research and development positions it as a key player in the pharmaceutical landscape, aiming to provide new treatment options for healthcare providers and patients alike. Read More
News & Press Releases
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · October 21, 2025
Via Benzinga · October 21, 2025
Via Benzinga · October 21, 2025
Citius Pharmaceuticals (NASDAQ: CTXR) Eyes $400M Market Opportunity with LYMPHIR Launch
Cancer rarely moves fast. It simmers. In the case of cutaneous T-cell lymphoma, or CTCL, it creeps beneath the skin for years, sometimes decades, before erupting into a full malignancy. Patients endure chronic pain, itching, and lesions while cycling through therapy after therapy, chasing control rather than cure. The condition is rare, devastating, and underserved. That is what makes the story of Citius Pharmaceuticals (NASDAQ: CTXR) so critical. Because while the disease moves slowly, Citius has not.
Via AB Newswire · October 16, 2025
Via Benzinga · September 19, 2025
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · June 25, 2025
Via Benzinga · June 24, 2025
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · June 24, 2025
Via Benzinga · June 20, 2025
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · June 20, 2025
Volume analysis on 2025-06-10: stocks with an unusual volume in today's session.
Via Chartmill · June 10, 2025
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · June 10, 2025
Citius announced a $15.8 million direct offering.
Via Benzinga · June 10, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · June 10, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · June 10, 2025
Via Benzinga · June 10, 2025
Via Benzinga · June 10, 2025
Via Benzinga · June 9, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · June 9, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · June 9, 2025
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) shares are trading higher Monday after the company announced it entered into a distribution services agreement with Cardinal Health.
Via Benzinga · June 9, 2025